Perimeter Medical Imaging AI

Big Milestone: @PerimeterMed's Claire™ has received premarket approval (PMA) from FDA. This represents a massive leap forward in our mission to transform the standard of care for #BreastCancer patients. Read more: bit.ly/4u7S4z2 #PerimeterAI #StrongerTogether

Proud to see Claire’s FDA approval featured in @RadiologyBiz. The 1st FDA-approved, #AI-enabled imaging device for intraop #breastcancer margin assessment—granted Breakthrough Device status and PCCP. 🔗 radiologybusiness.com/topics/medical… @MStempniak

Perimeter Medical Imaging AI is proud to partner with leading #healthcare providers like Dr. Sommer Gunia and support more informed surgical decision-making through our commercially available S-Series #OCT technology.

During #BreastCancer surgery, surgeons remove the tumor along with surrounding tissue called the margin. A pathologist later checks if cancer cells remain. Negative margins ➡️ no cancer at the edge. Positive margins ➡️ cancer cells still present. Margins matter.

Honored to hear @chamath highlight @PerimeterMed Claire recently cleared rigorous FDA PMA process, becoming the first AI-enabled imaging device for intraoperative breast cancer margin assessment. bit.ly/4bj8T1s (24:48 to 26:28) #HelloClaire $PINK $PYNKF

@fintactica @armchairtweets #HelloClaire #PerimeterAI #TSXV $PINK $PYNKF

Excited to see the interest in our recent FDA approval! Claire OCT+AI underwent rigorous PMA process, is used as an adjunctive tool to help surgeons identify areas suspicious for cancer, with the goal of reducing residual disease in the operating room. bit.ly/4ru5Tp5

Thrilled to see FDA approval for Claire featured in @DallasInnovates ! Check out the full story here: dallasinnovates.com/in-a-first-per… #DallasInnovation #MedTech #PerimeterAI #BreastCancerCare @SandraEngelland

This International Women’s Day, we celebrate the women who give their time, knowledge, leadership, and care — every single day. 💬 Tag a woman who inspires you and share one word about what you’ve gained from her support. #InternationalWomensDay #GiveToGain #IWD2026

#ICYMI Perimeter Claire™ is now FDA approved. We'd like to take a moment to recognize the people behind the scenes. Thank you for your brilliance, your grit & your commitment to transforming #BreastCancerCare. This milestone belongs to you. #EmployeeAppreciationDay

.@PerimeterMed gets FDA nod for imaging device for breast cancer surgery bioworld.com/articles/729361 #medtech #breastcancer #AI #imaging

Thank you to Layten Praytor and @DMagazine for covering of our latest milestone: FDA approval for Claire™ Read the full story here: dmagazine.com/healthcare-bus…

We had the privilege of hosting an intimate circle of breast surgeons and clinical leaders for an evening of conversation and to share the exciting news about the FDA Approval for Claire™. Thank you to the surgeons who joined us and shared their insights! #HelloClaire #Medtech

The CLAIRE™ OCT System represents an important regulatory milestone for @PerimeterMed . What makes this technology unique? - First AI-enabled imaging device cleared for use in breast cancer surgery in the United States - Establishes a newly recognized FDA device type — “OCT imaging system with AI/ML [artificial intelligence/machine learning] software for adjunctive detection of breast cancer” (FDA product code SHH), which demonstrates novelty - Approved through the FDA’s rigorous Premarket Approval (PMA) pathway, reflecting the highest standard of clinical evidence - Among the first Class III AI-enabled medical devices approved with a Predetermined Change Control Plan (PCCP), enabling structured, FDA-pre-reviewed updates to the algorithm over time which ensures we can provide the latest AI updates to our customers quickly. This milestone represents an important step forward for Perimeter and for the surgeons and patients we aim to support. CLAIRE is the first commercialization of an AI-driven imaging platform designed with the potential to expand across multiple oncologic applications as we continue advancing our mission to improve cancer surgery. We are proud to help pave the future path for AI-enabled medtech innovations that will improve the patient experience. $PINK.V $PYNKF

On #WorldEngineeringDay, we’re thanking the brilliant engineers who turned a vision into reality. Claire OCT+AI is now FDA-approved as an adjunctive imaging tool for intraoperative margin assessment during breast-conserving surgery Together, we see more. Thank you, engineers!

Four years ago, I invested ~$40M and got involved helping build a small publicly listed company in Canada called Perimeter Medical. Why? They were trying to build an AI enabled device to help doctors do cancer surgeries better: take a tumor out from a patient, analyze it with AI while still in the surgical theater and tell with precision if all the cancer was taken out. If yes, close the patient up. If not, go back and get all the cancer. Well, we got FDA approval today!! Our product, Claire, became the FIRST FDA-approved AI-enabled imaging device for breast cancer surgery. We also got Breakthrough Designation. Currently, ~20% of women face repeat surgeries because surgeons "didn't get it all". What’s even worse is that they typically don’t find out for 10 days after the surgery until pathology has reviewed the resected tumor. That is 10 days of waiting and worrying for patients. Claire’s real-time AI + OCT tech delivers 10x the resolution of standard X-rays, identifying suspicious tissue during a surgery so surgeons can act immediately. Claire is now a regulated tool that sits in the workflow, in real time, while a surgeon is operating. It is just the start for what this platform can do for cancer care. We will first focus on ~300,000 breast cancer surgeries per year in the U.S., and then grow into other solid tumors over time. From a systems perspective, it’s also what “real AI” looks like: invisible to the patient, indispensable to the clinician, and measured in fewer surgeries  and better treatment experience .   Congratulations to @adrianvmendes and the @perimetermed team.

Andrew Berkeley, CIO & Co-Founder at @PerimeterMed shares how our team focuses on advancing high-res OCT imaging, generating robust datasets, and refining intraoperative workflow integration. We believe the next chapter of surgical imaging is here. #PerimeterAI #StrongerTogether

From engineering breakthroughs to responsible, patient-centered development, Andrew Berkeley shares what continues to drive our team forward. Watch the full conversation here: linkedin.com/pulse/perimete… #Leadership #PerimeterAI #MedTech

Research shows that additional surgery is associated with higher rates of complications, with risk compounding in older patients and complex surgical cases. ⬇️ Swipe through for the data behind reoperation-related complications. #MedEdMinutes #BreastCancerAwareness

@PerimeterMed, now on Instagram! Join us there, hit that ❤️, and follow to stay on the edge of innovation with Perimeter. instagram.com/perimetermed_a… #NowOnInstagram #PerimeterAI #MedTech